Valuation: Kenvue Inc.

Capitalization 35.25B 30.39B 27.43B 26.32B 48B 3,239B 50.24B 324B 130B 1,553B 132B 129B 5,556B P/E ratio 2026 *
19.6x
P/E ratio 2027 * 17.9x
Enterprise value 42.85B 36.94B 33.35B 32B 58.35B 3,938B 61.06B 394B 158B 1,888B 161B 157B 6,753B EV / Sales 2026 *
2.76x
EV / Sales 2027 * 2.66x
Free-Float
99.66%
Yield 2026 *
4.63%
Yield 2027 * 4.75%
1 day+0.77%
1 week-3.82%
Current month-3.82%
1 month+1.43%
3 months+8.62%
6 months-1.24%
Current year+6.61%
1 week 17.93
Extreme 17.93
19.11
1 month 17.93
Extreme 17.93
19.18
Current year 16.56
Extreme 16.555
19.18
1 year 14.02
Extreme 14.02
25.17
3 years 14.02
Extreme 14.02
27.8
5 years 14.02
Extreme 14.02
27.8
10 years 14.02
Extreme 14.02
27.8
Manager TitleAgeSince
Chief Executive Officer 59 14/07/2025
Director of Finance/CFO 57 12/05/2025
Chief Tech/Sci/R&D Officer 57 -
Director TitleAgeSince
Chairman 70 01/05/2023
Director/Board Member 66 04/05/2023
Director/Board Member 58 08/05/2023
Change 5d. change 1-year change 3-years change Capi.($)
+0.77%-3.82%-21.48% - 35.25B
-0.23%-8.12%-12.69%+11.68% 357B
-2.39%-9.73%-4.78%+6.46% 144B
+0.96%-5.63%-3.29%+30.85% 74.99B
-1.30%-4.81%+0.96%-10.43% 62.59B
-3.29%-15.30%+26.48%-62.23% 33.54B
+1.89%-21.88%-36.84%-24.51% 21.32B
+0.23%-7.90%-11.98%-5.50% 19.61B
-1.40%-8.29%+6.82%+21.93% 12.43B
-1.91%-7.70%-3.47%-10.88% 9.24B
Average -0.67%-9.33%-6.03%-4.73% 77B
Weighted average by Cap. -0.66%-8.40%-8.10%+5.74%

Financials

2026 *2027 *
Net sales 15.54B 13.4B 12.1B 11.61B 21.17B 1,428B 22.15B 143B 57.29B 685B 58.34B 57.09B 2,450B 15.95B 13.75B 12.41B 11.91B 21.72B 1,466B 22.73B 147B 58.79B 703B 59.86B 58.58B 2,514B
Net income 1.82B 1.57B 1.42B 1.36B 2.48B 167B 2.59B 16.73B 6.7B 80.14B 6.82B 6.68B 287B 2B 1.72B 1.55B 1.49B 2.72B 183B 2.85B 18.37B 7.36B 87.99B 7.49B 7.33B 315B
Net Debt 7.6B 6.55B 5.91B 5.67B 10.35B 698B 10.83B 69.9B 28B 335B 28.51B 27.91B 1,197B 7.14B 6.15B 5.55B 5.33B 9.72B 656B 10.17B 65.66B 26.3B 314B 26.78B 26.21B 1,125B
Logo Kenvue Inc.
Kenvue Inc. is one of the world leaders in the design, manufacture and marketing of consumer healthcare products. The group offers products for health, beauty, baby care, oral care, skin care and more. Net sales break down by family of products as follows: - self care products (42,3%): for the treatment of coughs, colds, allergies, pain, indigestion, constipation, etc. (brands Zyrtec, Benadryl, Zarbee's, Frenadol, Codral, Reactine, Tylenol, Motrin, Calpol, Nicorette, Imodium, Pepcid, Microlax, Daktarin, etc.); - personal care products (30.3%): primarily oral care, baby care, women's health and wound care products (Listerine, Desitin, Carefree, Stayfree, Band-Aid, Neosporin brands, etc.); - beauty and skin care products (27.4%): hair care products, sun protection products, face and body care products, etc. (Neutrogena, Aveeno, Clean&Clear, Lubriderm, Johnsons, Neostrata, OGX, Rogaine brands, etc.). Product marketing is assured through direct sales, distributors and the Internet. Net sales are distributed geographically as follows: North America (49%), Europe-Middle East-Africa (23%), Asia-Pacific (19.3%) and Latin America (8.7%).
Employees
21,890
Date Price Change Volume
06/03/26 18.39 $ +0.77% 19,035,206
05/03/26 18.25 $ +0.33% 43,633,125
04/03/26 18.19 $ +0.22% 40,715,582
03/03/26 18.15 $ -3.92% 33,694,672
02/03/26 18.89 $ -1.20% 34,825,108
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
12
Last Close Price
18.39USD
Average target price
19.83USD
Spread / Average Target
+7.85%

Quarterly revenue - Rate of surprise